Sharon Cohen, MD, FRCPC
Medical Director, Toronto Memory Program
Assistant Professor, University of Toronto
Consultant Neurologist, North York General
Toronto, Ontario, Canada
Alireza Atri, MD, PhD
Director, Banner Sun Health Research Institute
Memory and Cognitive Disorders, Neurology
Banner Health
Sun City, Arizona

Program Description

Clinics that administer antiamyloid monoclonal antibodies (mAbs) require many resources, detailed protocols, and effective communication among multiple departments. Establishing these protocols and infrastructure can be challenging and must be individualized to the clinic’s resources. Drs. Sharon Cohen and Alireza Atri discuss the required clinic resources, strategies to making treatment decisions, and optimal ways to communicate with multiple departments and with patients or caregivers.

Target Audience

This activity is designed to address identified knowledge and practice gaps among neurology and primary care clinicians who manage patients with MCI or early AD.

Educational Objectives

  1. Describe infrastructure changes required in order to implement targeted therapies

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Preactivity Questions.
  3. Review the activity content.
  4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Disclosures of Conflicts of Interest

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sharon Cohen, MD, FRCPC Nothing to disclose.

Alireza Atri, MD, PhD Receipt of Royalty/Patient Holder: Book royalty from Oxford University Press (Medical Book on Dementia); Consulting Fees: AriBio Co. Ltd., Eisai Inc., Life Molecular Imaging GmbH, Lundbeck Inc., Merck & Co., Inc., Novo Nordisk Inc., ONO PHARMA USA, Inc., Prothena Biosciences Inc., Vaxxinity Inc. Contracted Research: Contracted research as site Principal Investigator with funding provided to my institution from National Institute on Aging/National Institutes of Health (NIH), Arizona Department of Health Services, Alzheon, Inc., Athira Pharma, Inc., Biogen Inc., Biohaven Ltd (with Alzheimer’s Disease Cooperative Study [ADCS]), Eisai Inc. (with Alzheimer’s Therapeutic Research Institute [ATRI]/Alzheimer’s Clincal Trials Consortium [ACTC]), Eli Lilly and Company (with ATRI/ACTC), Vivoryon Therapeutics NV (with ADCS), USC, Indiana University, Johns Hopkins, Washington University St. Louis, Gates Ventures, Foundation for NIH (FNIH), ACTC 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For questions about this activity, please contact us at info@exchangecme.com.

Begin Activity
available resources
linked resources
Suggested Reading

Making the Call in Alzheimer’s Disease

Optimizing Diagnosis and Management